vaccines

an Open Access Journal by MDPI

IMPACT FACTOR 3.4

Indexed in: PubMed

CITESCORE 7.7

Treatment of Orthopoxvirus Infections

Guest Editor:

Dr. Panayampalli Subbian Satheshkumar
Poxvirus and Rabies Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA

Deadline for manuscript submissions:
closed (15 February 2021)

Message from the Guest Editor

Dear Colleagues,

Smallpox remains the only human disease completely eradicated through a successful vaccination campaign. As routine smallpox vaccination of the general public was discontinued, the majority of the current population are naive to orthopoxvirus infection. Human orthopoxvirus infections are predominantly caused by monkeypox virus in Africa, cowpoxvirus in Europe, vaccinia virus in South America, and buffalopoxvirus in Asia. Due to the smallpox adverse effects caused by the replication of the competitive vaccinia virus in contraindicated individuals, a safer non-replicative vaccine was recently approved by the Food and Drug Administration (FDA). TPOXX was approved for smallpox treatments by FDA recently. There is a need for additional antivirals that target different steps in the orthopoxvirus lifecycle. Similarly, prophylactic treatment with antibodies against orthopoxviruses is needed. We hope this Special Issue will cover several of these important topics for treatment of orthopoxvirus infections.

Dr. Panayampalli Subbian Satheshkumar
Guest Editor

vaccines

IMPACT FACTOR 3.4 | Indexed in: PubMed | CITESCORE 7.7

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
𝕏@Vaccines_MDPI